FDA Asks Pfizer to Test Second Paxlovid Course in Patients With COVID-19 Rebound

FDA Asks Pfizer to Test Second Paxlovid Course in Patients With COVID-19 Rebound
Paxlovid, Pfizer's anti-viral medication to treat COVID-19, in a picture illustration taken in Medford, Mass., on May 12, 2022. Brian Snyder/Illustration/Reuters
|Updated:
0:00

The  Food and Drug Administration (FDA) has asked Pfizer Inc. to test the effects of an additional course of its antiviral Paxlovid among people who experience a rebound in COVID-19 after treatment, the regulator said on Friday.

The drugmaker must produce the initial results of a randomized controlled trial of a second course of the antiviral by Sep. 30 next year, the FDA told Pfizer in a letter dated Aug. 5.